

## Supplementary Data

SUPPLEMENTARY TABLE S1. AREA UNDER THE CURVE FOR RESTING FOREARM BLOOD FLOW, FREE FATTY ACID, TRIGLYCERIDES, AND INSULIN

<i>Variable</i>	<i>Drug</i>	<i>Prediabetes Study Subjects n=15</i>
Resting FBF (mL/min/100 mL tissue)	Exenatide	28.2 ± 2.9
	Saxagliptin	31.3 ± 2.9
	Placebo	35.7 ± 2.7
	% change	-21.0% ( <i>P</i> =0.131)
	Exenatide vs. placebo	
	% change	-12.3% ( <i>P</i> =0.523)
	Saxagliptin vs. placebo	
	% change	-9.9% ( <i>P</i> =0.749)
FFA (mmol/L)	Exenatide	2.26 ± 0.29
	Saxagliptin	1.62 ± 0.08
	Placebo	1.67 ± 0.11
	% change	35.3% ( <i>P</i> =0.053)
	Exenatide vs. placebo	
	% change	-3.0% ( <i>P</i> =0.963)
	Saxagliptin vs. placebo	
	% change	39.5% ( <i>P</i> =0.031)
Triglycerides (mg/dL)	Exenatide	741.17 ± 85.15
	Saxagliptin	1059.64 ± 132.83
	Placebo	1011.21 ± 132.50
	% change	-26.7% ( <i>P</i> =0.032)
	Exenatide vs. placebo	
	% change	4.8% ( <i>P</i> =0.998)
	Saxagliptin vs. placebo	
	% change	30.1% ( <i>P</i> =0.024)
Insulin (mIU/L)	Exenatide	87.50 ± 20.84
	Saxagliptin	212.35 ± 36.50
	Placebo	322.56 ± 6.02
	% change	-72.9% ( <i>P</i> =0.0006)
	Exenatide vs. placebo	
	% change	-34.2% ( <i>P</i> =0.131)
	Saxagliptin vs. placebo	
	% change	-58.8% ( <i>P</i> =0.067)
	Exenatide vs. saxagliptin	

Raw data are mean ± SEM. Differences between groups are expressed in percentages. FBF, forearm blood flow; FFA, free fatty acid; SEM, standard error of mean.